将计算机认知测试与血清生物标志物的结合改善了早期发病的神经退行性疾病的检测
Veera Tikkanen1,2, Teemu I Paajanen3, Anna-Leena Heikkinen1,2,4
1Research Unit of Clinical Medicine, Neurology, University of Oulu, Oulu, Finland.
Journal of Alzheimer's disease : JAD
|October 27, 2025
概括
早期诊断痴呆是一个挑战. 将血液生物标志物与计算机化的灵活注意力测试 (FAT) 结合起来,可以在记忆诊所早期查早期痴呆 (EOD).
科学领域:
- 神经学 神经学
- 生物化学 生物化学
- 认知科学 认知科学
背景情况:
- 早期痴呆症 (EOD) 的诊断很困难,通常依赖于专门的诊所.
- 执行功能障碍是EOD的一个关键症状,但缺乏初级保健的查工具.
- 血液生物标志物的进步和可访问的认知测试提供了新的诊断机会.
研究的目的:
- 评估血清生物标志物 (神经丝轻链,状纤维酸性蛋白质) 和计算机化的灵活注意力测试 (FAT) 以区分EOD.
- 在记忆诊所人口中评估这些新工具的综合诊断准确性.
- 将FAT的表现与传统的神经心理评估进行比较.
主要方法:
- 一组206名参与者 (症状发作≤65岁) 在24个月内进行了研究.
- 用单分子阵列分析血清生物标志物.
- 使用ROC和歧视性分析评估了差异性准确性;FAT与传统测试进行了比较.
主要成果:
- 血清生物标志物和认知测试的组合实现了检测EOD和MCI-n.的AUC为0.872.
- 脂肪与血清生物标志物相结合,在诊断中达到82.1%的准确性.
- 这种准确性与传统的神经心理测试与生物标志物 (82.3%) 相比较.
结论:
- 将血清生物标志物与计算机化FAT集成是早期EOD查的一个有希望的策略.
- 这种方法可以帮助识别需要在记忆诊所进一步评估的患者.
- 新的生物标志物和可访问的认知测试可以提高神经退行性疾病的早期检测.
关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.基于血液的生物标志物数字认知评估数字认知评估早期发作的痴呆症.状纤维化酸性蛋白质是状纤维化的.轻度的认知障碍 轻度的认知障碍神经纤维光链的光链.神经心理测试 神经心理测试更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
33.7K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.9K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
544
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
544
